
BiomX Inc. (PHGE) Stock Forecast & Price Target
BiomX Inc. (PHGE) Analyst Ratings
Bulls say
BiomX Inc. is making significant strides in the development of innovative phage therapies, particularly with its BX004 and BX011 product candidates targeting chronic pulmonary infections and diabetic foot osteomyelitis, respectively. The company recently received positive feedback from the FDA, which supports the advancement of BX011 into a Phase 2a study and indicates a clear regulatory pathway, enhancing the potential for market penetration and commercial success. Furthermore, BiomX's ability to broaden its valuation through additional indications and expansion beyond the U.S. market presents substantial upside opportunities for the firm's overall financial outlook.
Bears say
BiomX Inc faces significant financial challenges that contribute to a negative outlook on its stock, primarily stemming from the risk of failed or inconclusive clinical trials for its therapeutic candidates. The company's ability to secure adequate funding is also in question, which could hinder progress in drug development and may lead to dilutive capital raises. Furthermore, the lack of commercial success for its products poses a risk to achieving financial stability and growth.
This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.
BiomX Inc. (PHGE) Analyst Forecast & Price Prediction
Start investing in BiomX Inc. (PHGE)
Order type
Buy in
Order amount
Est. shares
0 shares